XML 70 R42.htm IDEA: XBRL DOCUMENT v3.6.0.2
Variable Interest Entities (Tables)
12 Months Ended
Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Investments in Unconsolidated Variable Interest Entities and Estimated Maximum Exposure to Loss

As of December 31, 2016, the Company’s investments in unconsolidated variable interest entities (“VIEs”) and its estimated maximum exposure to loss were as follows (in millions):

 

     Investments in
Unconsolidated
VIEs
  Maximum
Exposure to
Loss

NovaQuest Pharma Opportunities Fund III, L.P.

   $ 43      $ 51   

NovaQuest Pharma Opportunities Fund IV, L.P.

     6        18   
  

 

 

 

 

 

 

 

   $                 49      $             69